ET
MDGL icon

Entropy Technologies’s Madrigal Pharmaceuticals MDGL Stock Holding History

Entropy Technologies’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,626
Closed -$2.95M – 1120
2026
Q1 		$2.95M Sell
5,626
-1,316
-19% -$629K 0.14% 203
2025
Q4 		$4.04M Buy
6,942
+3,240
+88% +$1.65M 0.22% 130
2025
Q3 		$1.7M Buy
3,702
+1,800
+95% +$672K 0.13% 219
2025
Q2 		$576K Buy
1,902
+800
+73% +$238K 0.05% 438
2025
Q1 		$365K Buy
+1,102
New +$362K 0.04% 503

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Entropy Technologies's MDGL Position: Q2 2026 in Review

Entropy Technologies sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 5,626 shares — an estimated $2.95M sold.

Entropy Technologies first reported a position in MDGL in Q1 2025 and held it in 5 quarters. The position peaked at $4.04M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Entropy Technologies reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Entropy Technologies sold 5,626 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.95M.
  • Entropy Technologies first reported a position in Madrigal Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Entropy Technologies's Madrigal Pharmaceuticals position peaked at $4.04M in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.